ARTICLE | Emerging Company Profile
Upstream Bio targeting asthma heterogeneity with $200M
Investors OrbiMed, Maruho acquired the company’s lead candidate from Astellas via an auction
June 7, 2022 12:27 AM UTC
Upstream Bio thinks it can target asthma’s two major disease subtypes by hitting a receptor that sits above the distinct biological pathways that drive each one.
Debuting June 2 with a $200 million series A, Upstream Bio Inc. aims to take on inflammatory diseases including asthma by targeting TSLPR via lead candidate UPB-101, a mAb that co-lead investors OrbiMed Advisors and Maruho Co. Ltd. acquired from Astellas Pharma Inc. (Tokyo:4503) in an auction...